Indoco Remedies Management

Management Kriterienprüfungen 3/4

Indoco Remedies CEO ist Sundeep Bambolkar , ernannt in Feb 2012, hat eine Amtszeit von 12.75 Jahren. Die jährliche Gesamtvergütung beträgt ₹75.54M , bestehend aus 61.7% Gehalt und 38.3% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 0.18% der Aktien des Unternehmens, im Wert von ₹51.59M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 7.9 Jahre bzw. 14 Jahre.

Wichtige Informationen

Sundeep Bambolkar

Geschäftsführender

₹75.5m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	61.7%
Amtszeit als Geschäftsführer	12.8yrs
Eigentum des Geschäftsführers	0.2%
Durchschnittliche Amtszeit des Managements	7.9yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	14yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Sundeep Bambolkar im Vergleich zu den Einnahmen von Indoco Remedies verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	₹321m
Jun 30 2024	n/a	n/a	₹767m
Mar 31 2024	₹76m	₹47m	₹985m
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹1b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹65m	₹40m	₹1b
Dec 31 2022	n/a	n/a	₹2b
Sep 30 2022	n/a	n/a	₹2b
Jun 30 2022	n/a	n/a	₹2b
Mar 31 2022	₹46m	₹30m	₹2b
Dec 31 2021	n/a	n/a	₹1b
Sep 30 2021	n/a	n/a	₹1b
Jun 30 2021	n/a	n/a	₹1b
Mar 31 2021	₹28m	₹20m	₹930m
Dec 31 2020	n/a	n/a	₹734m
Sep 30 2020	n/a	n/a	₹571m
Jun 30 2020	n/a	n/a	₹393m
Mar 31 2020	₹18m	₹15m	₹241m
Dec 31 2019	n/a	n/a	₹302m
Sep 30 2019	n/a	n/a	₹264m
Jun 30 2019	n/a	n/a	₹111m
Mar 31 2019	₹15m	₹12m	-₹29m
Mar 31 2018	₹16m	₹12m	₹412m

Vergütung im Vergleich zum Markt: SundeepDie Gesamtvergütung ($USD894.85K) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt Indian ($USD264.36K).

Entschädigung vs. Einkommen: SundeepDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Sundeep Bambolkar (64 yo)

12.8yrs

Amtszeit

₹75,540,000

Vergütung

Mr. Sundeep Vasant Bambolkar has been a Joint Managing Director at Indoco Remedies Limited since February 15, 2012. Mr. Bambolkar served as Chief Financial Officer at Indoco Remedies Limited from March 23,...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Suresh Kare	Non-Executive Chairman & Whole time Director	61.3yrs	₹36.89m	4.7% ₹ 1.4b
Sundeep Bambolkar	Joint MD & Executive Director	12.8yrs	₹75.54m	0.18% ₹ 53.3m
Aditi Panandikar	MD & Executive Director	12.8yrs	₹85.42m	6.14% ₹ 1.8b
Pramod Ghorpade	Chief Financial Officer	3yrs	₹17.38m	keine Daten
Ramanathan Hariharan	GM of Legal	1.9yrs	₹5.48m	keine Daten
Kavita Inamdar	Chief Technical Officer	no data	₹7.57m	keine Daten
Ajay Karajagi	President of Sales & Marketing	no data	keine Daten	keine Daten
Rajesh Usgaonker	Chief Marketing Officer	no data	keine Daten	keine Daten
Rajan Saawant	Vice President of Corporate HR	no data	keine Daten	keine Daten
Prashant Pathak	Head of OSD	no data	keine Daten	keine Daten
Abhilash Soral	Executive Vice President of International Business for Regulated Markets	no data	keine Daten	keine Daten
Hemant Joshi	Senior Vice President of Sales for API	no data	keine Daten	keine Daten

7.9yrs

Durchschnittliche Betriebszugehörigkeit

60.5yo

Durchschnittliches Alter

Erfahrenes Management: 532612Das Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (7.9 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Suresh Kare	Non-Executive Chairman & Whole time Director	61.3yrs	₹36.89m	4.7% ₹ 1.4b
Sundeep Bambolkar	Joint MD & Executive Director	20.7yrs	₹75.54m	0.18% ₹ 53.3m
Aditi Panandikar	MD & Executive Director	20.7yrs	₹85.42m	6.14% ₹ 1.8b
Divakar Gavaskar	Independent Non-Executive Director	19.6yrs	₹580.00k	keine Daten
Rajiv Kakodkar	Independent Non-Executive Director	17.6yrs	₹660.00k	0.013% ₹ 3.8m
Anand Nadkarni	Non-Executive Director	10.5yrs	₹360.00k	keine Daten
Vasudha Kamat	Non-Executive & Independent Director	4.7yrs	₹500.00k	keine Daten
Abhijit Gore	Independent Non-Executive Director	4.1yrs	₹460.00k	0.0054% ₹ 1.6m
Satish Shenoy	Independent Director	less than a year	keine Daten	keine Daten
Ajay Mulgaokar	Independent Director	less than a year	keine Daten	keine Daten

14.0yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: 532612Die Vorstandsmitglieder sind sehr erfahren ( 14 ).

Indoco Remedies Management

Management Kriterienprüfungen 3/4

Wichtige Informationen

Jüngste Management Updates

MD & Executive Director recently bought ₹4.6m worth of stock

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Recent updates

MD & Executive Director recently bought ₹4.6m worth of stock

Price target decreased by 9.0% to ₹324

Second quarter 2025 earnings released: ₹1.09 loss per share (vs ₹3.82 profit in 2Q 2024)

Indoco Remedies Limited to Report Q2, 2025 Results on Oct 24, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Cetirizine Hydrochloride Tablets USP, 10 mg

Indoco Remedies Limited Declares Final Dividend for Financial Year Ended March 31, 2024

Dividend of ₹1.50 announced

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2024

Indoco Remedies Limited Receives Final ANDA Approval from the USFDA for Lofexidine Tablets 0.18 Mg with Competitive Generic Therapy Designation

First quarter 2025 earnings released: EPS: ₹0.20 (vs ₹2.62 in 1Q 2024)

Indoco Remedies Limited to Report Q1, 2025 Results on Jul 23, 2024

MD & Executive Director recently bought ₹3.1m worth of stock

Indoco Remedies Receives Tentative ANDA Approval from USFDA for Canagliflozin and Metformin Hydrochloride Tablets

Now 21% overvalued

Joint MD & Executive Director recently bought ₹1.2m worth of stock

Price target decreased by 8.8% to ₹360

Now 24% overvalued

Indoco Remedies Limited to Report Q4, 2024 Results on May 16, 2024

Indoco Remedies Limited Announces Cessation of Divakar M. Gavaskar and Rajiv P. Kakodkar as Independent Directors, Effective Mach 31, 2024

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2024 Results on Jan 23, 2024

Insufficient new directors

Indoco Remedies Limited to Report Q2, 2024 Results on Oct 19, 2023

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2023

Indoco Remedies Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q1, 2024 Results on Jul 25, 2023

MD & Executive Director recently bought ₹6.4m worth of stock

MD & Executive Director recently bought ₹1.6m worth of stock

Indoco Remedies Limited (NSEI:INDOCO) agreed to acquire a 85% stake in Florida Pharmaceutical Products, Inc. from Contract Pharmacal Corp. for $4 million.

Indoco Remedies Limited Recommends Dividend for the Financial Year 2022-2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q4, 2023 Results on May 23, 2023

MD & Executive Director recently bought ₹669k worth of stock

Insufficient new directors

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited to Report Q3, 2023 Results on Jan 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Indoco Remedies Limited Announces Executive Changes

Indoco Remedies Limited to Report Q2, 2023 Results on Nov 10, 2022

Indoco Remedies Limited Declares Final Dividend for the Financial Year Ended March 31, 2022

Indoco Remedies Limited Announces Anacipher CRO Clears USFDA Inspection with Zero 483S

Upcoming dividend of ₹2.25 per share

Indoco Remedies Limited, Annual General Meeting, Sep 22, 2022

Indoco Remedies Limited (BSE:532612) agreed to acquire 26% stake in Kanakal Wind Energy Private Limited for INR 8.64 million.

First quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.30 in 1Q 2022)

Indoco Remedies Limited to Report Q1, 2023 Results on Aug 09, 2022

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Indoco Remedies Limited Approves Dividend for the Financial Year 2021-2022

Indoco Remedies Limited to Report Q4, 2022 Results on May 17, 2022

Third quarter 2022 earnings: EPS exceeds analyst expectations

Second quarter 2022 earnings released: EPS ₹4.52 (vs ₹2.78 in 2Q 2021)

Upcoming dividend of ₹1.50 per share

First quarter 2022 earnings released: EPS ₹4.30 (vs ₹1.85 in 1Q 2021)

Consensus EPS estimates increase to ₹17.85

Investor sentiment improved over the past week

Chief Financial Officer Mandar Borkar has left the company

Full year 2021 earnings released: EPS ₹10.10 (vs ₹2.62 in FY 2020)

Indoco Remedies Limited Recommends Dividend for the Financial Year 2020-2021

Price target increased to ₹361

Indoco Announces the Launch of Brinzolamide Ophthalmic Suspension 1% in the US Market by Teva Pharmaceuticals

Third quarter 2021 earnings released: EPS ₹2.75 (vs ₹0.99 in 3Q 2020)

New 90-day high: ₹326

Indoco Remedies Limited to Report Q3, 2021 Results on Feb 09, 2021

New 90-day high: ₹313

Market bids up stock over the past week